
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra Inc. is positioned for a positive financial outlook, with expectations of sustaining mid-teens revenue growth over the next few years and potential acceleration into the high-teens by 2026, largely driven by new product launches and decreasing market headwinds, particularly in China. The company is anticipated to enhance both its gross and operating margins, alongside delivering earnings per share (EPS) growth that exceeds revenue growth. Additionally, the potential for rapid growth in its neurovascular franchise and increasing adoption within vascular treatments highlights Penumbra's capacity to outperform competitors and solidifies its status as a market leader with profitable operations.
Bears say
Penumbra Inc faces significant challenges that could adversely affect its financial performance, including increased competition in the mechanical thrombectomy sector and potential setbacks in new product approvals and market integration. The company's dependence on the U.S. market exposes it to risks related to changes in reimbursement practices, which could further dampen growth prospects. Additionally, slower customer acquisition and procedural dynamics, along with regulatory delays, heighten the risk of underperformance against both internal expectations and broader market conditions.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares